The forgotten pandemic?
"The emergence of anti-vaccine extremism demonstrated that the ghost of dogmatic individualism lived on"
Oxford begins human vaccine trials for deadly Nipah virus
The first in-human clinical trial of a vaccine against the deadly Nipah virus has been launched by Oxford.
Oxford malaria vaccine recommended for use by WHO
An Oxford malaria vaccine has been recommended for use by the World Health Organization (WHO). This is the second of two malaria vaccines produced...
Scientists highlight the importance of ethics in tackling the next global pandemic
Estimates predict that there is currently more than a one in four chance of another global pandemic in the next decade, and scientists are...
Oxford’s Ebola vaccine recommended by WHO for use against Uganda outbreak
A new Ebola virus vaccine developed by the Oxford Vaccine Group is one of three vaccines recommended for a trial in Uganda to combat...
A Glimpse at the Poonawalla Family’s Oxford Investments
In 1966, a prize thoroughbred horse, owned by the Poonawalla family, was bitten by a venomous snake. They sent the horse to the Haffkine...
COVID cases double among young people in Oxford following students’ return
COVID cases among those aged 20–24 in Oxford have doubled in the last week, according to new data reported by the government, in what may be the first indication of the impact of students returning to the city for Hilary Term.
Campaigners question potential government sale of £200m Oxford vaccine centre
A vaccine centre in Harwell, near Oxford, has been put up for sale by the government, prompting questions from MPs and observers about the implications of such a sale. The Vaccine Manufacturing Innovation Centre (VMIC) was at the heart of the government’s efforts to respond to future pandemics.
EU watchdog claims possible link between AstraZeneca and rare spinal condition
The European Medicines Agency’s (EMA) recommended adding a rare spinal inflammation called transverse myelitis (TM) as a possible, but very rare side effect of the AstraZeneca vaccine.
Oxford Vaccine Group Director advises against widespread fourth jabs
Upcoming COVID-19 vaccine shots should target the most vulnerable in the UK and low-income countries worldwide, instead of becoming a regular occurrence for the general population once every few months, says Professor Sir Andrew Pollard.
Paxlovid: How a new oral drug against COVID-19 was designed
Despite progress with vaccinations, the highly contagious Omicron variant has caused cases to surge. Along with other UK approved drugs such as Merck’s Molnupiravir, Pfizer’s oral treatment, Paxlovid, could be a useful tool for doctors to treat patients.
Oxford begins human trials for ebola vaccine
This vaccine is also unique in being multivalent - targeting multiple variants of the virus. By being able to target both Zaire and Sudan variants, the vaccine can be used in virtually all outbreaks and therefore governments can stockpile it, secure that it will be useful if a new outbreak appears.
2 billion doses of Oxford vaccine delivered
"Today, the vaccine is produced in fifteen different countries, with jabs having been delivered in over 170 countries. The Anglo-Swedish drugmaker initially rebuffed pressures to make a profit on its 2 billion vaccines, while its rivals netted billions in revenues. This year, AstraZeneca is set to make a loss on the vaccine of 3 cents per share, according to the Financial Times."
AstraZeneca will start making profits from Oxford vaccine
“AstraZeneca had previously promised that they would administer the jab on a not-for-profit basis 'at cost', and would only start to make money from the vaccine when Covid-19 was no longer considered to be a pandemic. "
